Previous Article | Next Article ![]()
Journal of Virology, February 1999, p. 1729-1733, Vol. 73, No. 2
Swiss Institute for Cancer
Research1 and
Institute for
Biochemistry,
Received 6 April 1998/Accepted 27 October 1998
Many mucosal pathogens invade the host by initially infecting the
organized mucosa-associated lymphoid tissue (o-MALT) such as Peyer's
patches or nasal cavity-associated lymphoid tissue (NALT) before
spreading systemically. There is no clear demonstration that serum
antibodies can prevent infections in o-MALT. We have tested this
possibility by using the mouse mammary tumor virus (MMTV) as a model
system. In peripheral lymph nodes or in Peyer's patches or
NALT, MMTV initially infects B lymphocytes, which as a consequence
express a superantigen (SAg) activity. The SAg molecule induces the
local activation of a subset of T cells within 6 days after MMTV
infection. We report that similar levels of anti-SAg antibody
(immunoglobulin G) in serum were potent inhibitors of the SAg-induced
T-cell response both in peripheral lymph nodes and in Peyer's patches
or NALT. This result clearly demonstrates that systemic antibodies can
gain access to Peyer's patches or NALT.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Systemic Antibodies Can Inhibit Mouse Mammary Tumor
Virus-Driven Superantigen Response in Mucosa-Associated
Lymphoid Tissues

*
Corresponding author. Mailing address: Swiss Institute
for Experimental Cancer Research, Ch-1066 Epalinges, Switzerland.
Phone: (41 21) 692 58 56. Fax: (41 21) 652 69 33. E-mail:
Jean-Pierre.Kraehenbuhl{at}isrec.unil.ch.
Present address: Centre d'Immunologie Pierre Fabre, 74164 Saint-Julien en Genevois Cedex, France.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»